 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolescents aged from three to 17 to treat symptoms of Fragile X syndrome FXS. The pharma group said factors including the so-called Tripledemic high rates of respiratory syncytial virus RSV, influenza and COVID-19 had led to higher-than-expected cancellations of initial screening visits at the trials investigational centers, leading to slower-than-anticipated enrollment. 